290 related articles for article (PubMed ID: 34865703)
1. Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?
Tran TH; Tasian SK
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101331. PubMed ID: 34865703
[TBL] [Abstract][Full Text] [Related]
2. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
Pui CH; Roberts KG; Yang JJ; Mullighan CG
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
[TBL] [Abstract][Full Text] [Related]
3. Why and how to treat Ph-like ALL?
Roberts KG
Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
[TBL] [Abstract][Full Text] [Related]
4. Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.
Alghandour R; Sakr DH; Shaaban Y
Ann Hematol; 2023 Jun; 102(6):1287-1300. PubMed ID: 37129698
[TBL] [Abstract][Full Text] [Related]
5. Philadelphia chromosome-like acute lymphoblastic leukemia.
Tasian SK; Loh ML; Hunger SP
Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
[TBL] [Abstract][Full Text] [Related]
6. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
7. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
Khan M; Siddiqi R; Tran TH
Semin Hematol; 2018 Oct; 55(4):235-241. PubMed ID: 30502852
[TBL] [Abstract][Full Text] [Related]
8. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
Wells J; Jain N; Konopleva M
Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
[TBL] [Abstract][Full Text] [Related]
9. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
[TBL] [Abstract][Full Text] [Related]
11. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia.
Thakral B; Jain N; Tang G; Konoplev S; Vega F; Medeiros LJ; Wang SA
Ann Diagn Pathol; 2021 Aug; 53():151767. PubMed ID: 34118580
[TBL] [Abstract][Full Text] [Related]
12. Philadelphia-Like Acute Lymphoblastic Leukemia: A Systematic Review.
Yadav V; Ganesan P; Veeramani R; Kumar V D
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e57-e65. PubMed ID: 33485429
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
15. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
Płotka A; Lewandowski K
Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
17. Clinical screening for Ph-like ALL and the developing role of TKIs.
Tran TH; Tasian SK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):594-602. PubMed ID: 36485164
[TBL] [Abstract][Full Text] [Related]
18. Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises.
Izraeli S
Curr Opin Hematol; 2014 Jul; 21(4):289-96. PubMed ID: 24848770
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
20. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
